Loading clinical trials...
Loading clinical trials...
A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy
Conditions
Locations
1
China
Hunan Cancer Hospital
Changsha, Hunan, China
Start Date
January 1, 2023
Primary Completion Date
December 30, 2025
Completion Date
June 1, 2026
Last Updated
July 18, 2025
NCT07347600
NCT05467891
NCT05660083
NCT07354022
NCT02422641
NCT06625775
Lead Sponsor
Hunan Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions